Related references
Note: Only part of the references are listed.Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome
Ulrik Fahnoe et al.
JOURNAL OF VIRAL HEPATITIS (2021)
Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent
Niels Mejer et al.
VIROLOGY (2020)
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection
Marianne Martinello et al.
HEPATOLOGY (2020)
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
HEPATOLOGY (2020)
EASL recommendations on treatment of hepatitis C: Final update of the series
Jean-Michel Pawlotsky et al.
JOURNAL OF HEPATOLOGY (2020)
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
Sanne Brun Jensen et al.
HEPATOLOGY (2019)
Interpreting Viral Deep Sequencing Data with GLUE
Joshua B. Singer et al.
VIRUSES-BASEL (2019)
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Jordi Llaneras et al.
JOURNAL OF HEPATOLOGY (2019)
Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure
Mei Lu et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C
Kate Childs et al.
JOURNAL OF HEPATOLOGY (2019)
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure
Elisabetta Degasperi et al.
JOURNAL OF HEPATOLOGY (2019)
Genome Sequence of an Unknown Subtype of Hepatitis C Virus Genotype 6: Another Piece for the Taxonomic Puzzle
Martin Schou Pedersen et al.
MICROBIOLOGY RESOURCE ANNOUNCEMENTS (2019)
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
Graham S. Cooke et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
Maria C. Sorbo et al.
DRUG RESISTANCE UPDATES (2018)
Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants
Judith M. Gottwein et al.
GASTROENTEROLOGY (2018)
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
Velia Chiara Di Maio et al.
JOURNAL OF HEPATOLOGY (2018)
Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world
Philippe Halfon et al.
JOURNAL OF HEPATOLOGY (2018)
Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial
Anne L. H. Ovrehus et al.
JOURNAL OF HEPATOLOGY (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals
Elena Perpinan et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Short-Duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial
Eric Lawitz et al.
HEPATOLOGY (2017)
ICTV Virus Taxonomy Profile: Flaviviridae
Peter Simmonds et al.
JOURNAL OF GENERAL VIROLOGY (2017)
From HCV To HBV Cure
Raymond F. Schinazi et al.
LIVER INTERNATIONAL (2017)
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)
Mark S. Sulkowski et al.
LIVER INTERNATIONAL (2017)
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
M. Bourliere et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens
Eleanor M. Wilson et al.
CLINICAL INFECTIOUS DISEASES (2016)
Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir
Kerry Townsend et al.
AIDS (2016)
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naive or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Edward J. Gane et al.
GASTROENTEROLOGY (2016)
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2016)
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Christoph Sarrazin
JOURNAL OF HEPATOLOGY (2016)
The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control
Jens Bukh
JOURNAL OF HEPATOLOGY (2016)
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
George Lau et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection
Anita Kohli et al.
ANNALS OF INTERNAL MEDICINE (2015)
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection A Randomized Trial
Gregory T. Everson et al.
ANNALS OF INTERNAL MEDICINE (2015)
Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance
Sanne B. Jensen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
From non-A, non-B hepatitis to hepatitis C virus cure
Jean-Michel Pawlotsky et al.
JOURNAL OF HEPATOLOGY (2015)
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
Marc Bourliere et al.
LANCET INFECTIOUS DISEASES (2015)
Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
Edward J. Gane et al.
GASTROENTEROLOGY (2014)
Share Paper
